Valuation

VCYTVeracyte Inc

StockNasdaqÉtats-UnisHealth careEU retail: available
5/10

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricVCYTSector medianvs median
P/E30,628,8 · n=1146 % above
P/B2,53,0 · n=19616 % below
P/S6,23,7 · n=20267 % above
EV/EBIT30,224,1 · n=10326 % above
Free-cash-flow yield4,7 %2,8 % · n=18769 % above
Dividend yield0,00 %0,00 % · n=215—
Return on equity8,8 %2,7 % · n=193230 % above
Return on invested capital10,0 %3,5 % · n=176181 % above
Gross margin71,7 %62,5 % · n=15215 % above
Net debt / EBITDA−2,371,19 · n=108298 % below

Value factor: 70 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

InstrumentP/EP/BEV/EBITFree-cash-flow yieldDividend yieldSmart Score
LLYEli Lilly & Co42,633,6—1,6 %0,6 %6/10
JNJJohnson & Johnson29,17,2—3,6 %2,1 %8/10
ABBVAbbVie79,9—33,53,6 %3,0 %5/10
MRKMerck114,68,7—4,4 %2,3 %8/10
UNHUnitedHealth25,13,418,66,7 %2,3 %9/10
TMOThermo Fisher Scientific35,74,735,22,9 %0,3 %8/10
AMGNAmgen26,319,724,04,4 %2,3 %6/10
GILDGILEAD—16,1—6,8 %2,1 %4/10
ABTAbbott28,53,426,84,1 %3,0 %5/10
PFEPfizer38,42,0—6,6 %5,9 %1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 juin 2026 · filed 31 juill. 2026